Skip to main content
FBT logo
FBT
(NYSEARCA)
First Trust NYSE Arca Biotechnology Index Fund
$265.78-- (--)
Loading... - Market loading

FBT ETF: First Trust NYSE Arca Biotechnology Index Fund - Price, Holdings & Analysis

First Trust NYSE Arca Biotechnology Index Fund Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$263.27 - $267.65
52-Week High$274.99
52-Week Low$173.98
Open$266.08
Volume40.58K
Average Volume (3M)54.60K
Assets (AUM)2.82B
Expense Ratio0.55%
Total Holdings32
Inception DateJun 19, 2006
1 Day Change-1.90%
1 Month Change3.85%
6 Month Change31.65%
YTD Change27.95%
1 Year Change49.49%
52-Week Change50.18%
5 Year Change54.20%
10 Year Change171.04%
50-Day MA$256.59
200-Day MA$222.01
RSI53.06
Stochastic %K22.08
Stochastic %D62.94
Annual Dividend$0.00
Dividend Yield0.00%
Last Dividend Ex-DateDec 13, 2024
Dividend Growth YoY-100.00%

Frequently Asked Questions About First Trust NYSE Arca Biotechnology Index Fund

What is the current price of FBT?

The latest FBT price is $265.78. The 52-week range is $173.97–$274.99. FBT has returned 50.2% over the past 52 weeks.

What is the expense ratio for FBT?

FBT's annual expense ratio is 0.55%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.

Does FBT pay dividends?

First Trust NYSE Arca Biotechnology Index Fund does not currently pay dividends. Check the ETF Screener for dividend-focused alternatives in the Equity category.

What are the top holdings of FBT?

FBT's largest holdings are Corcept Therapeutics Incorporated (5.8%), Veracyte, Inc (4.5%), NeoGenomics, Inc (4.4%) (combined weight: 14.7%). The fund holds 32 total positions. View the complete portfolio breakdown in the Holdings section.

How does FBT compare to similar ETFs?

Compare FBT (0.55% expense ratio, $2.82B AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.